Mammalian Polyclonal IgG Antibody Market Share, Size, Trends, Industry Analysis Report, By Type (Mouse, Rabbit, Horse, Goat, and Others); By Product; By Application; By End-User; By Region; Segment Forecast, 2023-2032

Mammalian Polyclonal IgG Antibody Market Share, Size, Trends, Industry Analysis Report, By Type (Mouse, Rabbit, Horse, Goat, and Others); By Product; By Application; By End-User; By Region; Segment Forecast, 2023-2032

The global mammalian polyclonal IgG antibody market size is expected to reach USD 1,980.10 million by 2032, according to a new study by Polaris Market Research. The report “Mammalian Polyclonal IgG Antibody Market Share, Size, Trends, Industry Analysis Report, By Type (Mouse, Rabbit, Horse, Goat, and Others); By Product; By Application; By End-User; By Region; Segment Forecast, 2023-2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing prevalence of chronic disorders & extensively growing need for antibodies for a wide range of immunoassay tests and therapeutic and analytical applications worldwide are among the prominent factors fueling the demand and growth of the market. In line with this, the significantly increasing investments by governments to develop and formulate effective novel vaccinations and injectables with the help of advanced technologies, coupled with innovation in creating mammalian antibodies by the many bio-pharma companies, are further expected to create huge growth opportunities.

For instance, according to a report published by the American Cancer Society, about 1.9 million new cancers were diagnosed, and 608,570 cancer deaths were reported in the United States. And cancer is the leading cause of death among children aged (1-14 years) after accidents.

In recent years, developing polyclonal antibodies without assay type specification allows laboratories to easily incorporate the polyclonal antibodies in currently existing resources and help avoid additional costs. These antibodies have found extensive applications in biochemical research for detecting denatured proteins and effectively examining diseases and their treatments, which has spurred market growth at a significant pace.

Mammalian Polyclonal IgG Antibody Market Report Highlights

The mouse segment is expected to grow at the highest CAGR during the anticipated period, mainly driven by its growing use of antibodies due to its same characteristics as humans.

The metabolic markers segment accounted for the largest market share in 2022 because of the growing use of metabolic markers across the globe to treat patients with diabetes.

ELISA segment is projected to account for a substantial market share over the forecast period due to its widespread use in a variety of antibody tests like Lyme diseases and viral infections

Pharmaceutical and biotechnology companies held the largest market share in 2022, which is highly accelerated by rapidly surging investments to develop more innovative products

North American dominated the global market in 2022, owing to the quick adoption of the latest technologies and the presence of highly-developed healthcare infrastructure in the area.

The global key market players include Thermo Fisher Scientific, Stemcell Technologies, Phoenix Pharmaceuticals, Cell Signaling Technologies, and Bio-Rad Laboratories

Polaris Market Research has segmented the mammalian polyclonal IgG antibody market report based on type, product, application, end-user, and region:

Mammalian Polyclonal IgG Antibody, Type Outlook (Revenue - USD Million, 2019 - 2032)

Mouse

Rabbit

Horse

Goat

Others

Mammalian Polyclonal IgG Antibody, Product Outlook (Revenue - USD Million, 2019 - 2032)

Cardiac Markers

Metabolic Markers

Renal Markers

Others

Mammalian Polyclonal IgG Antibody, Application Outlook (Revenue - USD Million, 2019 - 2032)

ELISA

Immunoturbidometry

Antibody Identification

Immunoelectrophoresis

Immunohistochemistry

Immunocytochemistry

Wester Blotting

Mammalian Polyclonal IgG Antibody, Application Outlook (Revenue - USD Million, 2019 - 2032)

Pharmaceuticals and Biotechnology Companies

Hospitals

Diagnostic Centers

Academic and Research Centers

Mammalian Polyclonal IgG Antibody, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa